1 / 4

Gene Therapy Market : Present Scenario And The Growth Prospects With Forecast 2021

Global gene therapy market is anticipated to reach USD 4,300 million by 2021. The demand for gene therapy is primarily driven by continuous technological advancements and successful progression of several clinical trials targeting treatments with strong unmet need.

Télécharger la présentation

Gene Therapy Market : Present Scenario And The Growth Prospects With Forecast 2021

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Gene Therapy Market: Present Scenario And The Growth Prospects With Forecast 2021 Global gene therapy market is anticipated to reach USD 4,300 million by 2021. The demand for gene therapy is primarily driven by continuous technological advancements and successful progression of several clinical trials targeting treatments with strong unmet need. Moreover, rising R&D spend on platform technologies by large and emerging biopharmaceutical companies and favorable regulatory environment will accelerate the clinical development and the commercial approval of gene therapies in the foreseeable future. Despite promise, the high cost of gene therapy represents a significant challenge for commercial adoption in the forecast period. Gene therapy involves inactivating a mutated gene that is not functioning properly and introducing a new gene to assist in fighting a disease. Overall, the field of gene therapy continues to mature and advance with many products in development and nearing commercialization. For instance, Spark Therapeutics received approval of Luxturna, a rare form inherited blindness in December 2017. Gene therapy market in late 2017 also witnessed the approvals of Gilead/Kite Pharma’s Yescarta and Novartis’ Kymriah in the cancer therapeutic area. Request Sample Copy of this Market@ https://www.alexareports.com/report-sample/9997 Gene therapy offers promise in the treatment of range of indications in cancer and genetic disorders. Large Pharmaceuticals and Biotechnology companies’ exhibit strong interest in this field and key among them include Allergan, Shire, Biomarin, Pfizer and GSK. The gene therapy space is witnessing a wave of partnerships and alliances. Pfizer has recently expanded its presence in gene therapy with the acquisition of Bamboo Therapeutics and Allergan entered the field, with the acquisition of RetroSense and its Phase I/II optogenetic program.

  2. North America holds a dominating position in the global gene therapy market which is followed by Europe and the Asia Pacific. The U.S. has maximum number of clinical trials ongoing followed by Europe. Moreover, the field of gene therapy in the U.S. and Europe continues to gain investor attention driven by success of high visible clinical programs and the potential of gene therapy to address strong unmet need with meaningful commercial opportunity. Moreover, the increasing partnerships and alliances and the disruptive potential of gene therapy bodes well for the sector through the forecast period. The study objectives are: We will give you an assessment of the extent to which the market possesses commercial characteristics (such as the presence of firms with primarily non- government business bases, the presence of business methods not consistent with public law/regulation/oversight including government acquisition) along with examples or instances of information that supports your assessment. We will also help you identify standard/customary terms and conditions such as discounts, warranties, buyer financing, inspection, and acceptance for the gene therapy market industry. We will further help you in knowing any pricing issues, price ranges, and analysis of price variations of products in gene therapy market industry. Furthermore, we will help you in identifying any historical trends to predict gene therapy market growth rate up to 2025. Lastly, we will predict the general tendency for supply and demand in the gene therapy market industries. Buying@ https://www.alexareports.com/send-an-enquiry/9997 Key Findings from the study suggest products accessible in the market are much competitive and manufacturers are progressively concentrating on advancements to pick up an aggressive edge. Companies are in a stage of development of new items in order to guarantee simple implementation and connection with the current gene. The hospatility segment is anticipated to grow at a high growth rate over the forecast period with the expanding utilization of smart locks inferable from expanding security-related worries among clients amid their stay at the hotels. North America is presumed to dominate the global smart locks market over the forecast years and Asia Pacific region shows signs of high growth owing to the booming economies of India, and China. Table of Contents: 1. Overview and Scope 1.1. History and Evolution of Gene Therapies 1.2. What is Gene Therapy 1.3. Types of Gene Therapy

  3. 1.4. Ex vivo and in vivo Approaches of Gene Therapy 1.5. RNAi Therapeutics 1.6. CAR-T Technology based Gene Therapy 1.7. Types of Vectors used for Gene Therapy 1.7.1. Viral 1.7.2. Non-Viral 2. Historical Marketed Gene Therapies [2003-2012] 2.1. Rexin-G (Epeius Biotechnologies Corporation) 2.2. Gendicine (SiBiono GeneTech Co., Ltd) 2.3. Neovasculgen [Human Stem Cells Institute (HSCI)) 2.4. Glybera (UniQure Biopharma B.V.) 3. First Countries to get an access to Gene Therapies 3.1. Philippines for Rexin-G [2003] 3.2. China for Gendicine [2003] 3.3. Russia for Neovasculgen [2011] 3.4. Selected European Countries for Glybera [2012] 4. Marketed Gene Therapies [Approved in Recent Years] 4.1. KYMRIAH (tisagenlecleucel) 4.1.1. Therapy Description 4.1.2. Therapy Profile 4.1.2.1. Company 4.1.2.2. Approval Date 4.1.2.3. Mechanism of Action 4.1.2.4. Researched Indication 4.1.2.5. Vector Used 4.1.2.6. Vector Type 4.1.2.7. Technology 4.1.2.8. Others Development Activities 4.1.3. KYMRIAH Revenue Forecasted till 2021 4.2. YESCARTA (axicabtagene ciloleucel) 4.2.1. Therapy Description 4.2.2. Therapy Profile 4.2.2.1. Company 4.2.2.2. Approval Date 4.2.2.3. Mechanism of Action 4.2.2.4. Researched Indication 4.2.2.5. Vector Used 4.2.2.6. Vector Type 4.2.2.7. Technology 4.2.2.8. Others Development Activities 4.2.3. YESCARTA Revenue Forecasted till 2021 4.3. LUXTURNA (voretigene neparvovec-rzyl)

  4. 4.3.1. Therapy Description 4.3.2. Therapy Profile 4.3.2.1. Company 4.3.2.2. Approval Date 4.3.2.3. Mechanism of Action and continue……… Ask For Discount@https://www.alexareports.com/check-discount/9997 About Us: Alexa Reports is a globally celebrated premium market research service provider, with a strong legacy of empowering business with years of experience. We help our clients by implementing decision support system through progressive statistical surveying, in-depth market analysis, and reliable forecast data. Alexa Reports is a globally celebrated premium market research service provider, with a strong legacy of empowering business with years of experience. We help our clients by implementing decision support system through progressive statistical surveying, in- depth market analysis, and reliable forecast data. Contact Us: Alexa Reports Ph no: +1-408-844-4624 / +91- 7030626939 Email: sales@alexareports.com Site: https://www.alexareports.com

More Related